登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
ClinicalTrials.gov 上登记的一项肺癌开放试验,由汕头大学医学院附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07071103,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
Patients with metastatic solid tumors (of any histology) without standard therapy options, who have previously received immunotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with anti-angiogenesis treatment and have shown disease progression.
入选标准第 5 条
Patients have complete clinical and pathological information.
入选标准第 8 条
Patients who have received pelvic and abdominal radiation therapy within 6 months prior to enrollment.
排除标准第 4 条
The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0 rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such as fatigue or hair loss).
排除标准第 5 条
ECOG level 0-2.
入选标准第 2 条
At least one accessible and measurable lesion should be selected as the target lesion for observation according to RECIST criteria.
入选标准第 4 条
Active hepatitis B, hepatitis C, HIV, or syphilis.
排除标准第 8 条
Pregnant or breastfeeding women.
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07071103,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥18 years, ≤80 years, regardless of gender. ECOG level 0-2. Expected life span>3 months. At least one accessible and measurable lesion should be selected as the target lesion for observation according to RECIST criteria. Patients with metastatic solid tumors (of any histology) without standard therapy options, who have previously received immunotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with anti-angiogenesis treatment and have shown disease progression. Patients should not be considered eligible for surgical treatment. Patients with brain metastases that are assessed as clinically stable after treatment through repeated CT and/or MRI scans are eligible. Patients have complete clinical and pathological information. Patients should not be borthered by any psychological, family, social or geographical conditions that may hinder compliance with the research protocol. Patients should be able to understand the informed consent form, voluntarily participate, and sign the informed consent form. Other indicators accord with the general inclusion criteria for clinical trials.排除标准:Exclusion Criteria:
Patients with contraindications to radiation therapy and immunotherapy. Previous occurrence of unacceptable immune related toxic side effects (immune myocarditis, pneumonia, etc.). Patients who were assessed as hyperprogressive disease (HPD). Patients who have received pelvic and abdominal radiation therapy within 6 months prior to enrollment. The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0 rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such as fatigue or hair loss). Patients with active uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment. Significant liver or kidney dysfunction (i.e., laboratory values >3 times the upper limit of normal). Active hepatitis B, hepatitis C, HIV, or syphilis. Brain disorders, symptomatic central nervous system (CNS) or meningeal metastases, or impaired cognitive function. Hypersensitivity to any drug included in the trial. Drug and/or alcohol abuse. Pregnant or breastfeeding women. Concurrent participation in another therapeutic clinical trial. Poorly controlled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within ≤14 days after intervention). Major surgery within 30 days. Use of antibiotics, antifungals, antivirals, antiparasitics, or probiotics within 4 weeks before enrollment.
引自 ClinicalTrials.gov, NCT07071103, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07071103,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。